For free samples, call 1-866-318-6977

For free samples, call 1-866-318-6977

OFFICE RESOURCES TO HELP GET PATIENTS STARTED ON THE INTRAVENOUS (IV) FORMULATION OF COSENTYX®

Start Form

Use this form to start patients on COSENTYX and simultaneously sign them up for support services.

Start Form

Start Form

Start Form (en español)

Start Form
(en español)

Insurance Resources

The following resources are designed to help you navigate coverage and reimbursement for your patients on COSENTYX.

Prior Authorizations, Exceptions & Appeals Kit

Interactive PDF with information and sample letters to help you navigate coverage for your patients on COSENTYX

IV Coding and Billing Guide

IV Billing & Coding Guide

Interactive PDF that provides an overview of billing and coding information related to the IV formulation of COSENTYX

IV Provider Co-Pay Portal

IV Provider Co-Pay Portal

Get eligible* IV patients started with the Co-Pay offer and submit claims for reimbursement

IV Co-Pay
												Enrollment

IV Co-Pay Enrollment

Information on how to get eligible* IV patients started with the Co-Pay offer and manage claims for reimbursement

IV Co-Pay Portal Guide Flashcard

IV Provider Co-Pay Portal Overview

Quick steps for navigating the IV Provider Co-Pay Portal

IV Specialty Pharmacy Commercial Co-Pay Claim Form

IV Specialty Pharmacy Co-Pay Claim Form

Specialty pharmacies may use this form when submitting a claim for the IV formulation of COSENTYX

IV Provider Commercial Co-Pay Claim Form

IV Provider Co-Pay Claim Form

Providers who buy and bill the IV formulation of COSENTYX may use this form when submitting a claim

IV Patient Co-Pay Claim Form

IV Patients Co-Pay Claim Form

Patients on the IV formulation of COSENTYX may use this form when submitting claims for reimbursement

Getting Started Resources

This comprehensive list of resources gives you the information you need to help your patients get started on the IV formulation of COSENTYX.

Distribution and Acquisition Flashcard

IV Distribution and Acquisition

Lists product-ordering information and the contact details of authorized distributors for offices directly acquiring the IV formulation of COSENTYX

Hospital Formulary Review Guide

IV Hospital Review Guide

Provides an overview of the IV formulation of COSENTYX to assist hospital formulary decision-makers

IV Comprehensive Onboarding Guide

IV Comprehensive Onboarding Guide

Includes information, tools, and resources for HCPs to use when dosing, administering, and billing for the IV formulation of COSENTYX

National Infusion Center Association (NICA) Infusion Center Locator

Buy and Bill Information

An overview of the buy and bill method of acquisition for specialty drugs

National Infusion Center Association (NICA) Infusion Center Locator

National Infusion Center Association (NICA) Infusion Center Locator

Conveniently locates the infusion centers near you and your patients. Novartis Pharmaceuticals Corporation does not endorse or recommend any specific infusion center

IV Dosing Calculator

IV Dosing Calculator

Comprehensive information to get patients started on the IV formulation of COSENTYX, including a dosing calculator, administration steps, and an instructional video

COSENTYX HIPAA Consent

HIPAA Consent

Direction on how patients can sign their Start Form electronically and provide authorization to have it processed

Electronic Medical Record (EMR) Support and Tip Sheets

The following resources are designed to support you when using your office's EMR system for COSENTYX.

EMA Start
																	Form

Electronic Medical Assistant® (EMA) Start Form

A preconfigured Start Form for COSENTYX that is ready to be integrated within EMA, the largest dermatology-specific EMR system

EMA Start Form Integration

EMA Start Form Integration

Provides information and instructions for integrating the EMA Start Form into the EMA EMR system

Epic PSS Integration Tip Sheet

Epic Patient Support Service Integration Tip Sheet

Provides information and instructions on how to access patient support resources within the Epic EMR system

Epic Favorite and Custom Med EHR Tip Sheet

Epic Favorites List Tip Sheet

Provides information and instructions on how to add favorite and custom medications within the Epic EMR system

Cerner PSS Integration Tip Sheet

Cerner Patient Support Service Integration Tip Sheet

Provides information and instructions on how to access patient support resources within the Cerner EMR system

Cerner Favorite and Custom Med EHR Tip Sheet

Cerner Favorites List Tip Sheet

Provides information and instructions on how to add favorite and custom medications within the Cerner EMR system

*Certain payers have carve-outs that restrict utilization of manufacturer support programs.

Limitations apply. Valid only for those with private insurance. Program provides up to $16,000 annually for the cost of COSENTYX and up to $150 per infusion (up to $1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions for details

HCP, healthcare professional; HIPAA, Health Insurance Portability and Accountability Act.

Electronic Medical Assistant (EMA) is a registered trademark of Modernizing Medicine.

3/24 304263



Expand ISI

INDICATIONS

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

WARNINGS AND PRECAUTIONS

Infections

Collapse ISI

INDICATIONS

COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in patients 6 years and older who are candidates for systemic therapy or phototherapy.

COSENTYX is indicated for the treatment of active psoriatic arthritis (PsA) in patients 2 years of age and older.

COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis (AS).

COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.

COSENTYX is indicated for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older.

COSENTYX is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients in COSENTYX. Cases of anaphylaxis have been reported during treatment with COSENTYX.

WARNINGS AND PRECAUTIONS

Infections

COSENTYX may increase the risk of infections. In clinical trials, a higher rate of infections was observed in COSENTYX treated subjects compared to placebo-treated subjects. In placebo-controlled clinical trials in subjects with moderate to severe PsO, higher rates of common infections, such as nasopharyngitis (11.4% versus 8.6%), upper respiratory tract infection (2.5% versus 0.7%) and mucocutaneous infections with candida (1.2% versus 0.3%) were observed in subjects treated with COSENTYX compared to placebo-treated subjects. A similar increase in risk of infection in subjects treated with COSENTYX was seen in placebo‑controlled trials in subjects with PsA, AS and nr-axSpA. The incidence of some types of infections, including fungal infections, appeared to be dose‑dependent in clinical trials.

In the postmarketing setting, serious and some fatal infections have been reported in patients treated with COSENTYX.

Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection. Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops a serious infection, monitor the patient closely and discontinue COSENTYX until the infection resolves.

Pre-treatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with COSENTYX. Avoid administration of COSENTYX to patients with active TB infection. Initiate treatment of latent TB prior to administering COSENTYX. Consider anti-TB therapy prior to initiation of COSENTYX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients closely for signs and symptoms of active TB during and after treatment.

Inflammatory Bowel Disease

Inflammatory Bowel Disease Inflammatory Bowel Disease (IBD) exacerbations, in some cases serious and/or leading to discontinuation of COSENTYX, occurred in COSENTYX treated subjects during clinical trials in PsO, PsA, AS, nr-axSpA, and HS. In adult subjects with HS, the incidence of IBD was higher in subjects who received COSENTYX 300 mg every 2 weeks (Ulcerative Colitis [UC] 1 case, EAIR 0.2/100 subject-years; Crohn’s Disease [CD] 1 case, EAIR 0.2/100 subject-years) compared to subjects who received COSENTYX 300 mg every 4 weeks (IBD 1 case, EAIR 0.2/100 subject-years). In addition, new onset IBD cases occurred in subjects treated with COSENTYX in clinical trials. In an exploratory trial in 59 subjects with active Crohn’s disease [COSENTYX is not approved for the treatment of Crohn’s disease], there were trends toward greater disease activity and increased adverse reactions in subjects treated with COSENTYX as compared to placebo-treated subjects.

Exercise caution when prescribing COSENTYX to patients with IBD. Patients treated with COSENTYX should be monitored for signs and symptoms of IBD.

Eczematous Eruptions

In postmarketing reports, cases of severe eczematous eruptions, including atopic dermatitis‑like eruptions, dyshidrotic eczema, and erythroderma, were reported in patients receiving COSENTYX; some cases resulted in hospitalization. The onset of eczematous eruptions was variable, ranging from days to months after the first dose of COSENTYX.

Treatment may need to be discontinued to resolve the eczematous eruption. Some patients were successfully treated for eczematous eruptions while continuing COSENTYX.

Hypersensitivity Reactions

Anaphylaxis and cases of urticaria occurred in COSENTYX treated subjects in clinical trials. If an anaphylactic or other serious allergic reaction occurs, administration of COSENTYX should be discontinued immediately and appropriate therapy initiated.

The removable caps of the COSENTYX Sensoready® pen and the COSENTYX 1 mL and 0.5 mL prefilled syringes contain natural rubber latex, which may cause an allergic reaction in latex-sensitive individuals. The safe use of the COSENTYX Sensoready pen or prefilled syringe in latex-sensitive individuals has not been studied.

Immunizations

Prior to initiating therapy with COSENTYX, consider completion of all age-appropriate immunizations according to current immunization guidelines. COSENTYX may alter a patient’s immune response to live vaccines. Avoid use of live vaccines in patients treated with COSENTYX.

MOST COMMON ADVERSE REACTIONS

Most common adverse reactions (>1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.

Please see full Prescribing Information, including Medication Guide.